| Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) (NCT03867084) | Merck Sharp & Dohme LLC | 2019-05-28 |
| Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma (NCT03895359) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2019-05-27 |
| EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI (NCT04012021) | University of Pisa | 2019-05-24 |
| Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients (NCT03776123) | Ipsen | 2019-05-15 |
| Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines (NCT05143619) | M.D. Anderson Cancer Center | 2019-05-10 |
| Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC (NCT03899428) | Humanity & Health Medical Group Limited | 2019-05-02 |
| A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (NCT03752398) | Xencor, Inc. | 2019-05-01 |
| Probiotics in the Prevention of Hepatocellular Carcinoma in Cirrhosis (NCT03853928) | Austral University, Argentina | 2019-05-01 |
| Adjuvant Radiotherapy Comparing TACE for Curative HCC (NCT02125396) | Guangxi Medical University | 2019-05-01 |
| Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (NCT03847428) | AstraZeneca | 2019-04-29 |
| Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma (NCT03867370) | Shanghai Junshi Bioscience Co., Ltd. | 2019-04-26 |
| A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence (NCT03945799) | Zhejiang University | 2019-04-22 |
| Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC (NCT03744247) | Sun Yat-sen University | 2019-04-21 |
| TCR-Redirected T Cells Therapy in Patient With HBV Related HCC (NCT03899415) | Beijing 302 Hospital | 2019-04-20 |
| Microbiota Study in Liver Transplanted Patients (NCT03507140) | University Hospital, Grenoble | 2019-04-16 |
| Phase II of Lenvatinib Plus Toripalimab for Advanced HCC (NCT03919383) | Sun Yat-sen University | 2019-04-15 |
| Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma (NCT03748927) | National Cancer Institute (NCI) | 2019-04-08 |
| Jiu-wei-zhen-xiao Granule for Advanced Hepatocellular Carcinoma (NCT03851471) | Zhong Wang | 2019-04-07 |
| Pretreatment Lymphocyte Monocyte Ratio on Outcome HCC Patients (NCT03869151) | Amany Aboalenen Amin | 2019-04-05 |
| A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection (NCT03914352) | Cancer Hospital of Guangxi Medical University | 2019-04-01 |
| HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC (NCT03780634) | Sun Yat-sen University | 2019-04-01 |
| Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (NCT02905188) | Baylor College of Medicine | 2019-03-28 |
| HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC (NCT03869034) | Sun Yat-sen University | 2019-03-25 |
| Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma (NCT03857815) | Shanghai Zhongshan Hospital | 2019-03-25 |
| The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) (NCT03896958) | SpeciCare | 2019-03-21 |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (NCT03829436) | Tempest Therapeutics | 2019-03-20 |
| Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC) (NCT04069468) | Boston Scientific Corporation | 2019-03-13 |
| RFA vs. SBRT for Small HCC (NCT03898921) | Sun Yat-sen University | 2019-03-10 |
| Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection (NCT03859128) | Shanghai Junshi Bioscience Co., Ltd. | 2019-03-05 |
| Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma. (NCT07664007) | Instituto de Investigación Sanitaria Aragón | 2019-03-04 |
| Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma (NCT04162158) | Beijing 302 Hospital | 2019-03-01 |
| Albumin for Hepatocellular Carcinoma (NCT03974074) | Guangxi Medical University | 2019-03-01 |
| HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial (NCT04667351) | Sun Yat-sen University | 2019-03-01 |
| Neoadjuvant Radiotherapy for HCC Involving Type I PVTT (NCT04025437) | Guangxi Medical University | 2019-03-01 |
| Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma (NCT03682276) | Imperial College London | 2019-03-01 |
| The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC) (NCT03851939) | Sun Yat-sen University | 2019-02-26 |
| NeuWave Microwave Ablation HCC China Study (NCT03783871) | Ethicon, Inc. | 2019-02-18 |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (NCT03841110) | Fate Therapeutics | 2019-02-15 |
| Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection (NCT03839550) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-02-15 |
| P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma (NCT04233840) | National Taiwan University Hospital | 2019-02-12 |
| A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. (NCT03794440) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-02-11 |
| A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (NCT03782207) | Hoffmann-La Roche | 2019-02-07 |
| Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection (NCT03812562) | Northwestern University | 2019-02-07 |
| The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC (NCT04800497) | University of Milano Bicocca | 2019-02-07 |
| Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer (NCT03812289) | OHSU Knight Cancer Institute | 2019-02-07 |
| Postoperative Adjuvant Therapy of HCC Based on PD-1 (NCT05307926) | Chen Xiaoping | 2019-02-01 |
| Adjuvant Therapies for Patients With HCC and MVI (NCT02436902) | Guangxi Medical University | 2019-02-01 |
| Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms (NCT06065592) | Lebanese University | 2019-02-01 |
| Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling (NCT06298123) | Chen Xiaoping | 2019-02-01 |
| Survival Analysis: TACE vs. Combination Therapy in HCC (NCT06261138) | Zhejiang University | 2019-02-01 |
| [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma (NCT03648073) | University of Alabama at Birmingham | 2019-01-30 |
| A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC (NCT03793725) | Yanqiao Zhang | 2019-01-30 |
| Perfusion and Dual Energy Computer Tomography in Hepatocellular Carcinoma (NCT03754192) | Assistance Publique - Hôpitaux de Paris | 2019-01-30 |
| A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies (NCT03829501) | Kymab Limited | 2019-01-28 |
| Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment (NCT03644511) | Bayer | 2019-01-24 |
| EXALT: EXercise Attenuates Liver Tumors Trial (NCT03979547) | Milton S. Hershey Medical Center | 2019-01-03 |
| HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC (NCT03803254) | Sun Yat-sen University | 2019-01-03 |
| Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma (NCT03838796) | Fudan University | 2019-01-03 |
| Comprehensive Prognostic Model: The Study Introduces a Novel Prognostic Model That Incorporates a Wide Range of Clinical and Laboratory Variables, Providing a More Holistic Approach to Predicting Overall Survival in HCC Patients (NCT06550739) | Haike Lei | 2019-01-01 |
| Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma (NCT06405321) | Guangxi Medical University | 2019-01-01 |
| By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation (NCT03880721) | Chinese PLA General Hospital | 2019-01-01 |
| Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma (NCT03807947) | Humanitas Clinical and Research Center | 2019-01-01 |
| Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates (NCT05276037) | University of Liege | 2019-01-01 |
| Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria (NCT03791918) | Sun Yat-sen University | 2019-01-01 |
| Yliver as a Test to Early Diagnose HCC (NCT03767764) | Corporacion Parc Tauli | 2018-12-27 |
| Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors (NCT03836352) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2018-12-21 |
| Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC (NCT03746249) | Sun Yat-sen University | 2018-12-17 |
| Adjuvant Therapy With Anlotinib for HCC (NCT04947371) | Shanghai Zhongshan Hospital | 2018-12-15 |
| The Assesment of MMP-1 Genotypes Polymorphism as a Risk Factor for HCC in Chronic HCV Patients With LC (NCT03722628) | Assiut University | 2018-12-15 |
| HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC (NCT03775395) | Sun Yat-sen University | 2018-12-12 |
| Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE (NCT03731910) | Seoul National University Hospital | 2018-12-11 |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667) | ImmunityBio, Inc. | 2018-12-11 |
| TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC (NCT03782831) | Sun Yat-sen University | 2018-12-11 |
| SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery (NCT03722875) | Shanghai Zhongshan Hospital | 2018-12-01 |
| The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC) (NCT03851887) | Sun Yat-sen University | 2018-12-01 |
| Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria (NCT03775707) | Shi Ming | 2018-12-01 |
| Hepatocellular Carcinoma in HIV-infected Individuals in Asian Population (NCT03702998) | Chinese University of Hong Kong | 2018-12-01 |
| Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma (NCT03738111) | Lee's Pharmaceutical Limited | 2018-12-01 |
| A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (NCT03778957) | AstraZeneca | 2018-11-30 |
| A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) (NCT04172571) | Akeso | 2018-11-22 |
| Liquid Biopsy-based Monitoring System for Relapse of HCC After Liver Transplantation: A Multi-center and Prospective Study (NCT03708705) | Zhejiang University | 2018-11-20 |
| Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular Carcinoma (NCT03668158) | Zhejiang University | 2018-11-20 |
| A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors (NCT03734926) | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | 2018-11-13 |
| Irradiation Stent Placement Plus TACE for HCC and PVTT (NCT03730675) | Zhongda Hospital | 2018-11-10 |
| Abbreviated MRI for HCC Surveillance (NCT03731923) | Seoul National University Hospital | 2018-11-08 |
| Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas (NCT04773769) | Auxilio Mutuo Cancer Center | 2018-11-07 |
| HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC (NCT03812783) | Sun Yat-sen University | 2018-11-05 |
| A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy (NCT04161911) | Bristol-Myers Squibb | 2018-10-29 |
| Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (NCT03539822) | Anwaar Saeed | 2018-10-22 |
| LiverMultiScan Analysis of MRI Scans in HCC (NCT04451603) | National Cancer Centre, Singapore | 2018-10-19 |
| Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation (NCT03630640) | Assistance Publique - Hôpitaux de Paris | 2018-10-11 |
| DKN-01 Inhibition in Advanced Liver Cancer (NCT03645980) | Johannes Gutenberg University Mainz | 2018-10-10 |
| RFA for Treatment of Intermediate Stage HCC (NCT05281783) | Benha University | 2018-10-01 |
| The Effect of Gut Microbiota on Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma (NCT04303286) | Tongji Hospital | 2018-10-01 |
| HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B (NCT03780049) | Sun Yat-sen University | 2018-10-01 |
| Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence (NCT03219372) | Cedars-Sinai Medical Center | 2018-09-27 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors (NCT03511222) | Washington University School of Medicine | 2018-09-11 |
| STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention (NCT03706742) | University of Texas Southwestern Medical Center | 2018-09-10 |
| A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations (NCT03781934) | Medivir | 2018-09-05 |